Advertisement

Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer

  • I. Desideri
  • G. Francolini
  • V. Scotti
  • D. Pezzulla
  • C. Becherini
  • F. Terziani
  • C. Delli Paoli
  • E. Olmetto
  • L. Visani
  • I. Meattini
  • D. Greto
  • P. Bonomo
  • M. Loi
  • B. Detti
  • L. Livi
Research Article
  • 57 Downloads

Abstract

Purpose

Here, we present the results from a retrospective analysis, with the purpose of evaluating the safety and feasibility of nivolumab and radiotherapy (RT) concomitant association in metastatic kidney and lung cancer patients.

Materials and methods

From August 2015 until September 2017, we retrospectively observed 20 patients with metastatic lung and renal cell carcinoma who had been initiated therapy with nivolumab and underwent concomitant RT. RT was administered either as an ablative therapy in the oligometastatic/oligoprogressive setting or as palliative-only treatment for symptomatic patients. Data on progression-free and overall survival (PFS and OS), treatment response and adverse events were collected and reported. Comparison between palliative-only and ablative treatments was performed.

Results

PFS and OS were 7 and 12.5 months in the entire population, respectively. Oligoprogressive patients treated with ablative intent, compared to patients undergoing RT with palliative-only intent, had statistically longer PFS (11.5 vs 5.2 months, HR 0.42, CI 0.18–0.98, p 0.03) and OS (17.9 vs 10.31 months, HR 0.41 CI 0.16–1.02, p 0.04). Considering only patients treated with ablative intent, 87.5% showed response to treatment, and complete response was reported in 37.5% of cases. Adverse G2–G3 related to combination treatment were reported as follows: 1 gastrointestinal (nausea), 4 breakthrough pain.

Conclusions

Our data showed significant advantage for oligoprogressive patients treated with RT during nivolumab therapy. No safety alert emerged. These results underline the potential synergistic effects of RT and Immune therapy combination. Our analysis prompts further prospective studies exploring the benefit of integrated treatment strategies.

Keywords

Metastatic kidney and lung cancer Nivolumab Stereotactic radiotherapy Immunotherapy 

Notes

Acknowledgements

None.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (“Comitato Etico Area Vasta Centro”) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–75.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2:846–56.CrossRefPubMedGoogle Scholar
  3. 3.
    Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64(21):7985–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Lugade AA, Sorensen EW, Gerber SA, et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180(5):3132–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Filatenkov A, Baker J, Mueller AM, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 2015;21(16):3727–39.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shiraishi K, Ishiwata Y, Nakagawa K, et al. Enhancement of antitumor radiation efficacy and consistent induction of the abscopal effect in mice by ECI301, an active variant of macrophage inflammatory protein-1alpha. Clin Cancer Res. 2008;14(4):1159–66.CrossRefPubMedGoogle Scholar
  11. 11.
    Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925–31.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1(6):365–72.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMedGoogle Scholar
  14. 14.
    Levy A, Massard C, Soria JC, et al. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: single centre subset analysis from a phase 1/2 trial. Eur J Cancer. 2016;68:156–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. Int J Radiat Oncol Biol Phys. 2017;98(2):344–51.CrossRefPubMedGoogle Scholar
  16. 16.
    Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors. J Clin Oncol. 2018;36(16):1611–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Pike LRG, Bang A, Ott P, et al. Radiation and PD-1 inhibition: favorable outcomes after brain-directed radiation. Radiother Oncol. 2017;124(1):98–103.CrossRefPubMedGoogle Scholar
  18. 18.
    Chen L, Douglass J, Kleinberg L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2018;100(4):916–25.CrossRefPubMedGoogle Scholar
  19. 19.
    Hubbeling HG, Schapira EF, Horick NK, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer. J Thorac Oncol. 2018;13(4):550–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924–33.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Escudier B, Motzer RJ, Sharma P, et al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with Nivolumab in CheckMate 025. Eur Urol. 2017;72(3):368–76.CrossRefPubMedGoogle Scholar
  22. 22.
    Nomura M, Otsuka A, Yoshimura M, et al. Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab. Cancer Chemother Pharmacol. 2018;81(5):823–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Fiorica F, Belluomini L, Stefanelli A, et al. Immune checkpoint inhibitor nivolumab and radiotherapy in pretreated lung cancer patients: efficacy and safety of combination. Am J Clin Oncol. 2018.  https://doi.org/10.1097/COC.0000000000000428.PubMedGoogle Scholar
  24. 24.
    Popp I, Grosu AL, Niedermann G, et al. Immune modulation by hypofractionated stereotactic radiation therapy: therapeutic implications. Radiother Oncol. 2016;120(2):185–94.CrossRefPubMedGoogle Scholar
  25. 25.
  26. 26.

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  • I. Desideri
    • 1
  • G. Francolini
    • 1
  • V. Scotti
    • 1
  • D. Pezzulla
    • 1
  • C. Becherini
    • 1
  • F. Terziani
    • 1
  • C. Delli Paoli
    • 1
  • E. Olmetto
    • 1
  • L. Visani
    • 1
  • I. Meattini
    • 1
  • D. Greto
    • 1
  • P. Bonomo
    • 1
  • M. Loi
    • 1
  • B. Detti
    • 1
  • L. Livi
    • 1
  1. 1.Radiation Oncology UnitAzienda Ospedaliera Universitaria Careggi, University of FlorenceFlorenceItaly

Personalised recommendations